Screener
Avalo Therapeutics AVTX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
FAQ
- What is Avalo Therapeutics's total liabilities?
- Avalo Therapeutics (AVTX) reported total liabilities of $42.12M in Q2 2026.
- How has Avalo Therapeutics's total liabilities changed year-over-year?
- Avalo Therapeutics's total liabilities increased by 91.4% year-over-year, from $22.01M to $42.12M.
- What is the long-term trend for Avalo Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Avalo Therapeutics's total liabilities has grown at a 11.7% compound annual growth rate (CAGR), from $19.19M to $33.41M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Avalo Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude